630 related articles for article (PubMed ID: 28456379)
1. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
Rivière I; Sadelain M
Mol Ther; 2017 May; 25(5):1117-1124. PubMed ID: 28456379
[TBL] [Abstract][Full Text] [Related]
2. CAR T-Cell Therapy: Progress and Prospects.
Wilkins O; Keeler AM; Flotte TR
Hum Gene Ther Methods; 2017 Apr; 28(2):61-66. PubMed ID: 28330372
[TBL] [Abstract][Full Text] [Related]
3. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.
Schubert ML; Hückelhoven A; Hoffmann JM; Schmitt A; Wuchter P; Sellner L; Hofmann S; Ho AD; Dreger P; Schmitt M
Hum Gene Ther; 2016 Oct; 27(10):758-771. PubMed ID: 27479233
[TBL] [Abstract][Full Text] [Related]
5. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
6. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
Frey NV; Porter DL
Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
[TBL] [Abstract][Full Text] [Related]
7. Design of chimeric antigen receptors with integrated controllable transient functions.
Juillerat A; Marechal A; Filhol JM; Valton J; Duclert A; Poirot L; Duchateau P
Sci Rep; 2016 Jan; 6():18950. PubMed ID: 26750734
[TBL] [Abstract][Full Text] [Related]
8. CAR T cell immunotherapy for human cancer.
June CH; O'Connor RS; Kawalekar OU; Ghassemi S; Milone MC
Science; 2018 Mar; 359(6382):1361-1365. PubMed ID: 29567707
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.
Barrett DM; Grupp SA; June CH
J Immunol; 2015 Aug; 195(3):755-61. PubMed ID: 26188068
[TBL] [Abstract][Full Text] [Related]
10. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
[TBL] [Abstract][Full Text] [Related]
11. Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety.
Gu X; He D; Li C; Wang H; Yang G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400287
[TBL] [Abstract][Full Text] [Related]
12. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.
Ruella M; Gill S
Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.
Jena B; Maiti S; Huls H; Singh H; Lee DA; Champlin RE; Cooper LJ
PLoS One; 2013; 8(3):e57838. PubMed ID: 23469246
[TBL] [Abstract][Full Text] [Related]
14. Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.
Ghorashian S; Amrolia P; Veys P
Exp Hematol; 2018 Oct; 66():5-16. PubMed ID: 30031849
[TBL] [Abstract][Full Text] [Related]
15. Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transfer.
Jin C; Fotaki G; Ramachandran M; Nilsson B; Essand M; Yu D
EMBO Mol Med; 2016 Jul; 8(7):702-11. PubMed ID: 27189167
[TBL] [Abstract][Full Text] [Related]
16. Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.
Gomes-Silva D; Mukherjee M; Srinivasan M; Krenciute G; Dakhova O; Zheng Y; Cabral JMS; Rooney CM; Orange JS; Brenner MK; Mamonkin M
Cell Rep; 2017 Oct; 21(1):17-26. PubMed ID: 28978471
[TBL] [Abstract][Full Text] [Related]
17. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
18. Future directions in chimeric antigen receptor T cell therapy.
Maude SL
Curr Opin Pediatr; 2017 Feb; 29(1):27-33. PubMed ID: 27841776
[TBL] [Abstract][Full Text] [Related]
19. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.
Lulla PD; Hill LC; Ramos CA; Heslop HE
Clin Adv Hematol Oncol; 2018 May; 16(5):375-386. PubMed ID: 29851933
[TBL] [Abstract][Full Text] [Related]
20. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
Terakura S; Yamamoto TN; Gardner RA; Turtle CJ; Jensen MC; Riddell SR
Blood; 2012 Jan; 119(1):72-82. PubMed ID: 22031866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
